Acesso a medicamentos para doenças crônicas no Brasil: uma abordagem multidimensional by Oliveira, Maria Auxiliadora et al.
1sDOI:10.1590/S1518-8787.2016050006161
Supplement PNAUM-ID 
Original Article
Rev Saúde Pública 2016;50(suppl 2):6s
Access to medicines for chronic diseases 
in Brazil: a multidimensional approach
Maria Auxiliadora OliveiraI, Vera Lucia LuizaI, Noemia Urruth Leão TavaresII, Sotero Serrate 
MengueIII, Paulo Sergio Dourado ArraisIV, Mareni Rocha FariasV, Tatiane da Silva Dal PizzolIV , Luiz 
Roberto RamosVII, Andréa Dâmaso BertoldiVIII
I Departamento de Política de Medicamentos e Assistência Farmacêutica. Escola Nacional de Saúde Pública 
Sérgio Arouca. Fundação Oswaldo Cruz. Rio de Janeiro, RJ, Brasil
II Departamento de Farmácia. Faculdade de Ciências da Saúde. Universidade de Brasília. Brasília, DF, Brasil
III Programa de Pós-Graduação em Epidemiologia. Faculdade de Medicina. Universidade Federal do Rio Grande 
do Sul. Porto Alegre, RS, Brasil
IV Departamento de Farmácia. Faculdade de Farmácia, Odontologia e Enfermagem. Universidade Federal do 
Ceará. Fortaleza, CE, Brasil
V Departamento de Ciências Farmacêuticas. Centro de Ciências da Saúde. Universidade Federal de Santa 
Catarina. Florianópolis, SC, Brasil
VI Departamento de Produção e Controle de Medicamentos. Faculdade de Farmácia. Universidade Federal do Rio 
Grande do Sul. Porto Alegre, RS, Brasil
VII Departamento de Medicina Preventiva. Escola Paulista de Medicina. Universidade Federal de São Paulo. São 
Paulo, SP, Brasil
VIII Departamento de Medicina Social. Faculdade de Medicina. Universidade Federal de Pelotas. Pelotas, RS, Brasil
ABSTRACT
OBJECTIVE: To analyze the access to medicines to treat non-communicable diseases 
in Brazil according to socioeconomic, demographic, and health-related factors, from a 
multidimensional perspective.
METHODS: Analysis of data from the National Survey on Access, Use and Promotion of 
Rational Use of Medicines (PNAUM), household survey, sampling plan by conglomerates with 
representativeness of the Brazilian population and large areas of the country, according to sex 
and age domains. Data collected in 2013–2014 with sample of adults (≥ 20 years) who reported 
having non-communicable diseases and medical indication for use of medicines (n = 12,725). 
We assessed the prevalence of access to medicines for self-reported non-communicable diseases, 
considering four dimensions: availability, geographic accessibility, acceptability, and affordability. 
We applied Pearson’s Chi-square test to assess the statistical significance of the differences 
between strata, considering the level of significance of 5%. 
RESULTS: We found prevalence of 94.3%, 5.2%, and 0.5% for full, partial, and null access, respectively. 
Higher prevalence was observed among seniors in the South compared to the Northeast; for those 
who reported having one non-communicable disease compared to those who reported having two 
or more; for those who needed one medicine compared to those who needed three or more; and for 
those who self-assessed their health as good or very good. Geographic accessibility was similar in 
the Unified Health System and in the private pharmacies (72.0%). Total availability of medicines was 
45.2% in the Unified Health System, 67.4% in the Popular Pharmacy Program, and 88.5% in private 
pharmacies. Acceptability was 92.5% in the Unified Health System, 97.8% in the Popular Pharmacy 
Program, and 98.7% in private pharmacies. As to affordability, 2.6% of the individuals failed to take 
the medicines they should in the 30-day period prior to the interview due to financial difficulty. 
CONCLUSIONS: Prevalence of full access to medicines for non-communicable diseases in 
Brazil is high and presents significant differences for age group, region of the country, number 
of non-communicable diseases, and for medicines prescribed and self-assessment of health. The 
major barriers to access to medicines were identified in the dimensions analyzed. 
DESCRIPTORS: Adult. Aged. Drug Utilization. Chronic Disease. Socioeconomic Factors. Health Surveys. 
Correspondence: 
Maria Auxiliadora Oliveira 
Rua Leopoldo Bulhões, 1480 sala 
627 Manguinhos  
21041-210 Rio de Janeiro, RJ, Brasil 
E-mail: dora@ensp.fiocruz.br
Received: 31 Jan 2015
Approved: 9 Aug 2016
How to cite: Oliveira MA, Luiza 
VL, Tavares NUL, Mengue SS, 
Arrais PSD, Farias MR, et al. Access 
to medicines for chronic diseases 
in Brazil: a multidimensional 
approach. Rev Saude Publica. 
2016;50(suppl 2):6s.
Copyright: This is an open-access 
article distributed under the 
terms of the Creative Commons 
Attribution License, which permits 
unrestricted use, distribution, and 
reproduction in any medium, 
provided that the original author 
and source are credited.
http://www.rsp.fsp.usp.br/
2s
Access to medicines for chronic diseases Oliveira MA et al.
DOI:10.1590/S1518-8787.2016050006161
INTRODUCTION
Medicines save lives and improve the health of people, preventing, curing, or controlling 
and reducing morbidity and mortality associated with acute and chronic diseases2. Access 
to medicines is a fundamental human right11 and results from the interaction of a complex 
network of processes, events, actors and their interests, including research and development 
institutions, chemical and pharmaceutical industries, regulatory agencies, health systems 
and health services, which also includes the medicine user10,15. 
In addition to access to health services for medical consultation, diagnosis and prescription, 
the effective access to medicines depends on their physical availability in pharmacy; on the 
users’ geographic accessibility to pharmacy services; on the users’ acceptability in relation 
to pharmacy services; and on the affordability of providers or individuals and families5,14. 
Study that discusses the main theoretical models prescribed in the literature to analyze the 
access to medicines in the level of health services recognizes these dimensions as core4.
In Brazil, the non-communicable diseases (NCD) are the main source of burden of disease, 
disproportionately affect the poorest populations, and were responsible for 72.0% of the mortality 
in 201116. The rapid demographic transition, with an increase in the relative weight of adults and 
seniors in the population pyramid, indicates trend of increasing for the burden of these diseases 
and for consumption of medicines in the country23. Control of these diseases and of their risk 
factors depends on a set of health actions, which includes timely health care and adequate 
provision of medicines16. In Brazil, besides the private market supply, these medicines are available 
for free in public health services (SUS), including primary health care7 and pharmacies of the 
Popular Pharmacy Program (FPFP)24. This program is a strategy to scaling up access, in which a 
set of medicines is supplied for free and another, broader, is sold at subsidized pricesa. 
Household surveys of national scope that included questions about access to medicines, such 
as the World Health Survey8 (2003) and the Assessment of Pharmaceutical Services in Brazil19 
(2005), reported prevalence of access to medicines from 87.0% to 89.0%. The National Health 
Survey (2013) reports lower prevalence for global access (82.5%)12. Study on access to medicines of 
continuous use with women with NCD in Brazil found an overall prevalence of access of 87.0%13.
Study with adults and seniors with NCD in two regions of the country20 reported general 
prevalence of access to medicines of continuous use of 78.8% in the Northeast and 83.7% in 
the South. Study with senior population in Brazil who reported long-term use of medicines 
showed prevalence of full access of 86.0%27. 
No studies with national representativeness were found that detailed the access to medicines for 
the set of most prevalent NCD in Brazil, according to the four dimensions proosed in this study. 
Considering the international commitment to reduce morbidity and mortality by NCD 
and the efforts developed to meet these goals16, it is necessary to analyze if the increasing 
government spending with medicines resulted in effective access to them by the Brazilian 
population. The possibility of addressing the issue according to the dimensions of access 
enables identifying weak points in the current pharmaceutical services policy in the country 
and proposing measures to better guide improvement processes. 
This study aimed to analyze the access to medicines to treat non-communicable diseases 
in Brazil according to socioeconomic, demographic, and health-related factors, from a 
multidimensional perspective. 
METHODS
The household survey component of the National Survey of Access, Use, and Promotion of 
Rational Use of Medicines (PNAUM) was a population-based study with cross-section design 
and sampling plan by conglomerates with representativeness of the Brazilian population 
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and of large regions of the country, according to sex and age domains. Data collection was 
conducted from September 2013 to February 2014 with face-to-face interviews in households 
and application of questionnaires. The instruments used were developed by a group of 
Brazilian researchers specialized on the areab and the data collected was stored in electronic 
device (tablet PC). Further details about the sampling and about the data collection logistics 
are described in the methodological article of the PNAUM18. 
This study considered a sample of adults aged 20 years or older who reported having some 
NCD diagnosed by physician: “Has a physician ever told you that you have hypertension 
or high blood pressure and medical indication for use of medicines?”. This question was 
repeated for each chronic disease investigated in the study (n = 12,725). Access to medicines 
is the outcome variable of this study.
A group of NCD (hypertension or high blood pressure; cardiovascular diseases, chronic 
obstructive pulmonary disease, diabetes, arthritis, depression) was investigated by applying a 
specific questionnaire, which included questions about the prior existence of other diseases for 
six months or more at the time of the interview. Data collection also considered aspects related 
to access in the main sources of supply of medicines of Brazil, which are: pharmacies of the 
Unified Health System (FSUS) public network; pharmacies of the Popular Pharmacy Program: 
public network and private pharmacies (FPFP), and private pharmacies in general (Fprivadas).
The independent variables analyzed were: sex ( female; male); age group (20-39; 40-59; 60 years old 
or older); educational level in completed school cycles (0-4; 5-8; 9-11; 12 years or more); economic 
classification (A/B; C; D; E) according to the Brazil Economic Classification Criterion, developed 
by the Brazilian Association of Survey Companies (CCEB 2013/ABEP – http://www.abep.org/); 
geographical region of residence (North; Northeast; Southeast; South, Midwest); number of 
NCD reported (1; 2; 3 or more); number of medicines needed (1; 2; 3-4; 5 or more) and self-
assessment of health (very good or good; regular; bad or very bad). The age group cut-off points 
were determined by the sampling domains.
The theoretical model employed was prescribed by Penchansky and Thomas22 and adapted 
by Luiza and Bermudez14 to evaluate the access to medicines. This model assumes that 
access to medicines results from the interaction of four dimensions: (i) physical availability: 
relation between type and quantity of medicines needed and type and quantity of products 
supplied; (ii) affordability: relation between prices of medicines and capacity to pay for them; 
(iii) geographical accessibility: relation between the location of medicines providers and the 
location of the user; (iv) acceptability: fit between characteristics of products and services 
and expectations and needs of users (Figure). 
Access to medicines for NCD was studied with all individuals who reported having medical 
indication for medicine (n = 12,725) based on the question: “In the last 30 days, have you 
been out of any of these medicines for some time?”. Those who reported having obtained all 
medicines prescribed by the physician were considered with full access to treatment. Partial 
access, whenever the user declared to have obtained some of the medicines prescribed by 
the physician or to have been out of some of those that should have been obtained in the last 
30 days due to unavailability on FSUS or to financial difficulty; and null access, whenever 
the user declared to have obtained none of the medicines prescribed by the physician in the 
last 30 days due to unavailability on FSUS or to financial difficulty. 
Indicators of the first three dimensions of access described below, all dichotomously 
categorized, were calculated for each source of provision of medicines investigated (FSUS, 
FPFP, and Fprivadas) when the respondent declared to be user of one of them, that is, had 
obtained at least one of the medicines prescribed by the physician at the source. Geographic 
accessibility was estimated considering the proportion of users who obtained at least one 
medicine prescribed by the physician and reported that the location was neither difficult 
to reach nor far. Total availability was considered whenever the user declared to have 
obtained all the medicines prescribed in the source considered and that no medicine had 
b The national team of the National 
Survey on Access, Use, and 
Promotion of Rational Use of 
Medicines (PNAUM) can be found 
at the PNAUM Web site: http://
www.ufrgs.br/pnaum/equipe
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ever been unavailable. Acceptability was considered whenever the user assessed the hours 
of operation and the quality of the service they used. The question offered the possibilities of 
the Likert scale with five points, re-categorized into: very good or good; regular; bad or very 
bad. Affordability was considered whenever the respondent declared having been out of one 
of the medicines prescribed by the physician in the last 30 days due to financial difficulty. 
Analysis of the four dimensions aims to identify potential barriers that users of the pharmacy 
services are facing to obtain access to medicines for NCD prescribed by the physician.
The data were stored and analyzed in the program SPSS, v. 20.0 for Windows (SPSS Inc., Chicago, 
IL, USA), using the CSPLAN command set suitable for the analysis of complex samples and 
ensuring the necessary sample weighting. For all variables we estimated percentages and 
their 95% confidence intervals and applied Pearson’s Chi-square tests to assess the statistical 
significance of the differences between strata, considering the level of significance of 5%.
The project was approved by the National Commission of Ethics in Research 
(CONEP – Protocol 18947013.6.0000.0008) and by the Research Ethics Committee of the 
Universidade Federal do Rio Grande do Sul (Protocol 19.997). All interviews were conducted 
only after the informed consent form was read and signed by the respondent or legal guardian in 
the case of individuals unable to answer their own questionnaire and those aged under 15 years.
RESULTS
Most persons (94.3%) reported having full access to medicines for the NCD under analysis, 
with some significant differences in the categories measured. Full access was higher: among 
those aged over 60 years; in the South, compared to the Northeast; among those who reported 
having one NCD; and among those who needed one medicine and self-assessed their health 
as very good or good (Table 1).
Figure. Logical model of access to medicines and questions that guided the construction of the indicators to evaluate each of the dimensions. 
PNAUM, Brazil, 2014.
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Table 1. Access to medicines for non-communicable diseases in adults and seniors (≥ 20 years), according 
to socioeconomic, demographic, and health-related variables. PNAUM, Brazil, 2014.
Variable
Prevalence of access to medicines for NCD
Full Partial Null
pb
%a 95%CI %a 95%CI %a 95%CI
Sex 0.025
Male 95.6 94.3–96.6 3.9 2.9–5.2 0.5 0.3–0.9 -
Female 93.6 92.4–94.6 5.8 4.9–7.0 0.6 0.4–0.8 -
Age group (years) < 0.001
20-39 91.2 87.5–93.8 7.5 4.9–11.3 1.3 0.8–2.3 -
40-59 93.5 92.2–94.6 5.8 4.7–7.0 0.7 0.5–1.1 -
≥ 60 96.2 95.3 –96.9 3.7 3.0–4.6 0.1 0.04–0.1 -
Educational levelc 0.032
0-4 95.1 93.9–96.0 4.4 3.5–5.5 0.5 0.3–0.9 -
5-8 95.1 93.7–96.3 4.5 3.4–5.9 0.4 0.2–0.7 -
9-11 92.6 90.7–94.2 6.8 5.2–8.7 0.6 0.3–1.1 -
≥ 12 95.1 92.7–96.7 4.3 2.7–6.6 0.7 0.3–1.6 -
Region < 0.001
North 93.6 91.1–95.4 4.7 3.2–6.9 1.7 0.9–3.2 -
Northeast 92.0 90.2–93.5 6.8 5.4–8.6 1.2 0.8–1.9 -
Southeast 94.9 93.4–96.1 4.8 3.7–6.4 0.3 0.1–0.6 -
South 95.8 94.4–96.9 3.9 2.9–5.2 0.3 0.1–0.8 -
Midwest 93.9 92.2–95.2 5.8 4.5–7.3 0.3 0.1–0.8 -
CCEBd 0.004
A/B 96.4 94.7–97.5 3.2 2.1–4.9 0.4 0.1–1.0 -
C 94.1 93.0–95.1 5.5 4.5–6.6 0.5 0.3–0.7 -
D 92.8 90.5–94.6 6.1 4.5–8.3 1.1 0.6–2.0 -
E 90.8 85.3–94.3 8.7 5.2–14.2 0.5 0.2–1.4 -
Number of NCD < 0.001
1 96.7 95.7–97.5 2,5 1.8–3.5 0,7 0.5–1.1 -
2 93.5 91.7–94.9 5,9 4.6–7.6 0,6 0.3–1.1 -
≥ 3 91.3 89.7–92.8 8,5 7.1–10.1 0,2 0.1–0.4 -
Number of medicines needede < 0.001
1 97.0 95.7–98.0 2.7 1.8–4.0 0.3 0.1–0.6 -
2 94.4 92.7–95.7 5.5 4.2–7.2 0.2 0.04–0.7 -
3-4 94.2 92.4–95.5 5.8 4.5–7.6 -
≥ 5 91.1 88.4–93.2 8.9 6.8–11.6 -
Self-assessment of health < 0.001
Very good/Good 96.5 95.5–97.3 3.1 2.3–4.1 0.4 0.2–0.7 -
Regular 93.2 91.8–94.3 6.2 5.1–7.6 0.6 0.4–1.0 -
Bad/Very bad 86.8 83.6–89.4 12.4 9.8–15.5 0.8 0.4–1.8 -
All 94.3 93.4–95.1 5.2 4.4–6.0 0.5 0.4–0.7 -
NCD: non-communicable diseases
a Percentage adjusted by sample weights and by post-stratification according to age and sex.
b Pearson’s Chi-squared test.
c In completed grades in school.
d According to the 2013 Brazil Economic Classification Criterion (CCEB 2013) of the Brazilian Association of 
Research Companies (ABEP). Available from: http://www.abep.org
e Medicines prescribed by the physician.
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Table 2. Geographic accessibility to the SUS pharmacy services, Popular Pharmacy Program and 
private pharmacy, according to socioeconomic, demographic, and health-related variables. PNAUM, 
Brazil, 2014.
Variable
Geographic accessibility to pharmacy services
SUS pharmacy Popular pharmacy Private pharmacy
%a 95%CI %a 95%CI % a 95%CI
Sex 0.007b 0.064b 0.165b
Male 75.3 71.4–78.8 70.8 65.6–75.6 73.9 70.3–77.1
Female 70.7 67.9–73.4 65.5 61.3–69.4 71.7 68.9–74.3
Age group (years) 0.057b 0.151b 0.110b
20-39 67.4 61.7–72.6 60.0 50.0–69.3 68.3 62.5–73.7
40-59 74.1 70.5–77.3 68.5 63.5–73.0 73.3 69.9–76.4
≥ 60 72.0 68.6–75.3 68.1 64.4–71.6 73.2 70.5–75.8
Educational levelc 0.597b 0.643b 0.898b
0-4 71.8 67.6–75.6 69.3 64.4–73.8 73.2 67.9–76.2
5-8 73.2 69.6–76.4 65.6 59.8–71.0 72.6 68.3–76.6
9-11 71.2 67.7–74.6 66.3 60.9–71.3 71.8 68.5–74.8
≥ 12 74.7 69.3–79.4 66.8 58.9–73.7 72.2 66.7–77.1
Region 0.012b 0.005b 0.140b
North 59.5 53.5–65.3 54.3 47.0–61.4 69.4 64.2–74.1
Northeast 74.4 69.8–78.5 61.1 54.9–66.9 69.6 64.5–74.3
Southeast 71.6 66.8–75.9 70.8 64.8–76.1 75.2 70.5–79.3
South 77.1 73.0–80.8 69.4 63.4–74.8 71.3 66.2–75.9
Midwest 67.0 61.1–72.4 59.1 51.5–66.4 68.3 62.4–73.7
CCEBd 0.162b 0.001b 0.001b
A/B 75.4 71.1–79.2 73.7 67.6–79.0 77.8 74.0–81.3
C 72.2 68.9–75.3 65.8 61.4–69.9 71.3 68.2–74.1
D 68.7 63.1–73.7 57.6 50.5–64.5 65.7 60.1–70.8
E 74.4 63.4–82.9 80.2 67.4–88.8 72.8 61.3–81.9
Number of NCD 0.455b 0.002b 0.021b
1 73.1 68.9–76.9 72.8 68.5–76.7 74.5 71.1–77.6
2 72.6 69.4–75.6 65.3 60.0–70.2 73.0 69.7–76.0
≥ 3 70.7 67.4–73.8 63.1 57.7–68.2 68.9 64.8–72.8
Number of medicines 
needede
0.001b < 0.001b 0.001b
1 77.3 72.5–81.4 72.0 65.9–77.4 75.8 71.7–79.4
2 73.2 69.1–77.0 74.5 68.9–79.3 76.2 72.6–79.6
3-4 73.0 69.3–76.3 66.9 61.7–71.7 71.7 68.4–74.7
≥ 5 67.6 63.9–71.1 59.9 53.8–65.7 68.1 63.7–72.2
Self-assessment of health 0.001b 0.001b 0.001b
Very good/Good 74.6 70.6–78.2 73.3 69.7–76.5 76.4 73.6–79.0
Regular 71.9 68.9–74.6 62.7 57.6–67.5 69.7 66.3–73.0
Bad/Very bad 62.6 57.4–67.6 58.0 49.6–65.9 64.4 59.0–69.4
All 72.3 69.5–74.9 67.3 63.7–70.7 72.4 69.7–74.9
SUS: Brazilian Unified Health System; NCD: non-communicable diseases
a Percentage adjusted by sample weights and by post-stratification according to age and sex.
b Pearson’s Chi-squared test.
c In completed grades in school.
d According to the 2013 Brazil Economic Classification Criterion (CCEB 2013) of the Brazilian Association of 
Research Companies (ABEP). Available from: http://www.abep.org
e Medicines precribed by the physician.
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Table 3. Availability of all medicines needed to treat non-communicable diseases in adults and seniors in 
the SUS pharmacies, Popular Pharmacy Program, and private pharmacies, according to socioeconomic, 
demographic, and health-related variables. PNAUM, Brazil, 2014.
Variable
Percentage of availability of medicines needede
SUS pharmacy Popular pharmacy Private pharmacy
%a 95%CI %a 95%CI %a 95%CI
Sex < 0.001b 0.294b 0.810b
Male 50.0 46.0–54.0 69.2 64.7–73.4 88.7 86.3–90.8
Female 42.7 39.6–45.9 66.4 62.9–69.7 88.4 87.0–89.7
Age group (years) 0.456b 0.017b 0.166b
20-39 46.5 40.0–53.0 59.1 49.0–68.5 85.9 80.9–89.7
40-59 43.8 40.3–47.3 71.6 67.1–75.6 89.5 87.8–90.9
≥ 60 46.2 42.6–49.9 65.5 62.1–68.8 88.6 87.2–89.9
Educational levelc 0.923b 0.226b 0.133b
0-4 45.8 41.4–50.2 64.7 60.4–68.7 87.9 86.1–89.5
5-8 45.5 40.9–50.0 70.8 65.3–75.8 90.3 88.0–92.1
9-11 44.4 40.6–48.2 69.1 64.6–73.3 89.3 87.2–91.1
≥ 12 46.1 40.1–52.2 67.4 59.5–74.5 85.8 81.0–89.6
Region < 0.001b < 0.001b 0.000b
North 41.7 36.0–47.5 71.7 63.6–78.6 88.6 85.8–91.0
Northeast 31.6 27.9–35.6 54.3 48.4–60.0 82.7 79.4–85.6
Southeast 51.8 47.1–56.5 68.1 63.4–72.5 91.1 89.4–92.5
South 45.8 41.9–49.8 74.5 70.0–78.5 89.6 87.4–91.4
Midwest 33.0 28.5–37.9 72.1 66.6–77.0 87.7 85.3–89.9
CCEBd 0.499b 0.594b 0.719b
A/B 44.2 39.9–48.7 68.8 63.4–73.7 88.6 86.3–90.6
C 45.7 42.4–49.0 67.5 64.1–70.7 88.8 87.5–90.1
D 45.7 40.6–50.8 65.9 59.0–72.2 88.0 84.9–90.6
E 38.5 29.9–47.9 58.6 40.7–74.4 85.0 72.0–92.6
Number of NCD < 0.001b < 0.001b 0.042b
1 56.6 52.4–60.6 74.1 70.2–77.7 90.0 88.4–91.4
2 41.7 37.9–45.6 67.5 62.5–72.1 87.9 85.8–89.8
≥ 3 32.6 29.4–35.9 60.5 55.9–64.8 87.2 85.0–89.1
Number of medicines 
needede
< 0.001b < 0.001b 0.633b
1 57.2 52.4–61.8 75.6 70.5–80.0 89.4 87.4–91.1
2 47.4 43.4–51.4 69.1 63.1–74.5 88.7 86.6–90.6
3-4 41.2 37.7–44.8 65.0 60.0–69.7 87.8 85.2–90.0
≥ 5 29.4 25.3–33.8 57.6 52.5–62.6 87.8 85.1–90.0
Self-assessment of health < 0.001b < 0.001b 0.322b
Very good/Good 54.0 50.3–57.6 72.9 69.1–76.5 89.3 87.5–90.8
Regular 39.0 35.9–42.1 63.5 59.6–67.3 88.1 86.3–89.6
Bad/Very bad 30.3 26.1–34.8 56.8 48.6–64.7 86.9 83.3–89.9
Full 45.2 42.2–48.2 67.4 64.4–70.2 88.5 87.3–89.6
SUS: Brazilian Unified Health System; NCD: non-communicable diseases
a Percentage adjusted by sample weights and by post-stratification according to age and sex.
b Pearson’s Chi-squared test.
c In completed grades in school.
d According to the 2013 Brazil Economic Classification Criterion (CCEB 2013) of the Brazilian Association of 
Research Companies (ABEP). Available from: http://www.abep.org
e Medicines prescribed by the physician. 
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Table 4. Acceptability related to the SUS pharmacy services, Popular Pharmacy Program, and private 
pharmacy, according to socioeconomic, demographic, and health-related variables. PNAUM, 
Brazil, 2014.
Variable
Acceptability to the pharmacy services
SUS pharmacy Popular pharmacy Private pharmacy
%a 95%CI %a 95%CI %a 95%CI
Sex 0.589b 0.601b 0.500b
Male 92.6 90.5–94.2 98.1 96.7–98.9 98.5 97.7–99.1
Female 92.1 90.5–93.3 97.7 96.4–98.5 98.8 98.3–99.2
Age group (years) 0.008b 0.390b 0.386b
20-39 91.1 87.1–94.0 95.0 88.4–98.0 98.3 96.6–99.1
40-59 90.8 88.9–92.4 98.3 97.2–99.0 98.6 97.8–99.1
≥ 60 94.0 92.6–95.2 98.1 97.1–98.7 99.0 98.5–99.4
Educational levelc 0.678b 0.077b 0.660b
0-4 92.7 91.0–94.0 98.3 97.2–99.0 98.5 97.7–99.0
5-8 92.5 90.3–94.0 98.2 97.1–98.9 99.2 98.6–99.6
9-11 92.1 89.6–94.0 96.5 93.7–98.1 98.6 97.6–99.2
≥ 12 90.7 86.7–93.6 98.8 96.4–99.5 98.8 97.7–99.4
Region 0.001b 0.001b 0.413b
North 84.2 80.0–87.7 88.9 84.2–92.4 97.1 95.4–98.2
Northeast 88.8 86.4–87.7 96.3 94.3–97.7 98.3 97.4–98.9
Southeast 93.4 91.0–95.2 98.5 96.6–99.4 98.9 98.3–99.8
South 95.1 92.9–96.7 99.0 96.4–99.5 99.4 98.3–99.8
Midwest 90.0 86.4–92.7 98.6 96.4–99.5 98.5 97.0–99.3
CCEBd 0.814b 0.781b 0.466b
A/B 92.9 89.3–95.4 98.1 96.4–99.0 98.9 97.9–99.4
C 92.3 90.6–93.7 97.7 96.3–98.6 98.8 98.3–99.2
D 91.3 88.8–93.3 97.5 95.6–98.6 98.3 96.8–99.2
E 92.1 83.9–96.3 98.6 95.6–99.6 97.1 90.5–99.2
Number of NCD 0.104b 0.237b 0.075b
1 93.3 91.5–94.7 97.3 94.9–98.3 98.6 97.8–99.1
2 91.0 90.5–94.7 98.4 97.3–99.1 99.1 98.4–99.5
≥ 3 91.8 89.7–93.6 98.2 96.3–99.2 98.6 97.8–99.1
Number of medicines 
needede
0.948b 0.531b 0.075b
1 92.3 89.5–94.4 97.3 95.3–98.4 98.5 97.4–99.1
2 92.3 89.9–94.2 97.5 93.6–99.0 98.0 96.3–98.9
3-4 92.6 90.6–94.3 97.8 96.1–98.8 98.8 98.1–99.2
≥ 5 91.9 89.9–93.6 98.6 97.6–99.2 99.3 98.7–99.6
Self-assessment of health 0.001b 0.168b 0.142b
Very good/Good 98.4 97.5–99.0 98.4 97.5–99.0 99.0 98.2–99.4
Regular 90.3 88.0–92.2 97.3 95.6–98.3 98.3 97.7–98.8
Bad/Very bad 92.2 90.8–93.4 97.3 94.1–98.8 99.2 98.2–99.6
All 92.2 90.8–93.4 97.8 96.9–98.5 98.7 98.3–99.0
SUS: Brazilian Unified Health System; NCD: non-communicable diseases
a Percentage adjusted by sample weights and by post-stratification according to age and sex.
b Pearson’s Chi-squared test.
c In completed grades in school.
d According to the 2013 Brazil Economic Classification Criterion (CCEB 2013) of the Brazilian Association of 
Research Companies (ABEP). Available from: http://www.abep.org
e Medicines prescribed by the physician.
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Geographic accessibility was similar for FSUS (72.3%) and FPrivadas (72.4%) and lower 
for FPFP (67.3%), but with no significant differences (Table 2). Individuals who reported 
better accessibility to the FSUS were those residing in the South compared to the North 
and Midwest, those who needed one medicine compared to those who needed five or 
more, and those who assessed their health as very good or good compared to those who 
reported worse self-perception of health. For FPFP, geographic accessibility was better in 
the Southeast compared to the North, for individuals belonging to class E compared to 
class D, for those who reported one NCD compared to those who reported three or more 
NCD, for those who needed one or two medicines compared to those who needed five 
or more, as well as for individuals with better self-perception of health. For Fprivadas, 
better geographic accessibility was reported by those belonging to class A/B compared 
to class D, by those who needed two medicines compared to those who needed five 
or more medicines, and by those who self-assessed their health as very good or good 
compared to bad or very bad (Table 2).
Total availability of medicines was higher for Fprivadas (88.5%) compared to FPFP 
(67.4%) and to FSUS (45.2%). For FSUS, availability was higher for men; for those who 
resided in the South and Southeast compared to the Midwest and Northeast; for those 
who reported having one NCD; for those who needed one medicine; and for those who 
showed better self-perception of health. For FPFP, reported total availability was higher 
in the South compared to the Northeast; for individuals who reported having one NCD 
compared to those who reported having three or more; for those who needed one 
medicine compared to those who needed three or more; and for those who self-assessed 
their health as very good or good. For Fprivadas, reported total availability was higher 
for users of the Southeast compared to the Northeast, with no significant differences 
for the other variables analyzed (Table 3). 
Acceptability related to pharmacy services was higher for Fprivadas (98.7%) in relation to 
FSUS (92.2%). For FSUS, we observed higher acceptability for users aged 60 years or older 
compared to those aged 40–59 years; for residents of the South, but with no significant 
difference in relation to the Southeast region; and for those who showed better self-perception 
of health. Users of the FPFP reported lower acceptability in the North compared to the other 
regions of the country. For Fprivadas, no significant differences were found for the variables 
analyzed (Table 4).
For affordability, 2.6% of adults and seniors reported having been out of some of the medicines 
needed in the 30 days prior to the interview due to financial difficulty. 
DISCUSSION
This study shows high prevalence of full access to medicines for NCD in adults and seniors 
in Brazil (94.3%). The sum of the prevalences of full and partial access (99.5%) indicates that 
almost all respondents who reported having medical diagnosis and indication for treatment 
of NCD managed to obtain some of the medicines they needed.
Despite the high prevalence of full access, we observed significant differences  between regions, 
socioeconomic levels, and health conditions. This indicates strengthening of pharmaceutical 
services in Brazil, but also the need to improve the pharmaceutical services – especially in 
the Northeast – and the health care provided to the poorest and sickest.
Study on disparity of access13 found prevalence of 87.0% for women of higher 
socioeconomic level and with one or two NCD and lower prevalence for women of 
lower socioeconomic level and with three or more NCD. Study on access to medicines 
for NCD with adults and seniors in two regions of the country in 200520 observed global 
prevalence of access of 84.0%, which, similarly to this study, was lower for adults (81.0%) 
than for seniors (87.0%). The higher prevalence of full access observed in this study may 
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reflect both improved supply of free medicines for NCD in FSUS and FPFP and improved 
income of the population. 
Study26 that analyzed the access to medicines for NCD in five countries of different income 
levels (low, medium-low, and medium-high) – Uganda, Ghana, Kenya, Philippines, and 
Jordan – found prevalence of access of up to 50.0%, ranging from 16.0% to 50.0%.
The theoretical model adopted in this study – used for the first time in household survey 
employing self-reported information – enabled identifying some barriers and significant 
differences in the independent variables analyzed for the four dimensions, enabling detailed 
description of the dynamics of access (Figure). 
Geographical accessibility to the three models of provision was regular (≈ 70.0%) and 
with no significant differences between them. Geographic accessibility to FSUS presented 
different regional disparities in relation to those identified in general analysis of access, 
showing that the geographic distribution of FSUS can be improved – especially in the North 
and Midwest – to better meet the needs of access to pharmacy services of the sickest. 
Accessibility to FPFP presented differences concerning region, socioeconomic level, and 
health conditions, indicating the need to promote better geographic distribution of the 
program, especially in the North, Northeast, and Midwest. Study on accessibility to FPFP 
found similar result in relation to geographic coverage9. Accessibility to Fprivadas showed 
no regional differences. However, as in the case of FPFP, it was better for the richest and 
less sick. Although regular accessibility represents a potential barrier to access, the high 
prevalence of full access observed in this study indicates that users of the three services 
were able to overcome it.
Higher total availability of medicines in Fprivadas compared to FPFP and to FSUS may be 
related to the fact that, differently from the private pharmacies, those linked to the SUS 
and to the Popular Pharmacy Program provide more restricted sets of medicines. The FSUS 
provide the medicines considered essential, that is, those that meet the health needs of each 
location, municipality, or state. The FPFP also provide two sets of medicines: one with about 
100 pharmaceutical products in the public network, another one more restricted and for the 
treatment of a group of NCD in the network of private pharmacies24,c,d. 
However, this result may reflect the low availability of essential medicines in the SUS 
(58.5%) observed in national evaluation of key medicine availability in SUS basic health 
units17. A population-based study on access to medicines in the SUS6 found even lower 
prevalence (45.8%). Another study on free access to medicines for hypertension and 
diabetes21 showed that the Family Health Strategy was more effective to ensure free 
access in the Northeast (62.4%) than in the South (39.6%) and than in traditional models 
of provision. The results for availability of this study show the complexity involved in 
obtaining access to all medicines for more than one NCD. These people, who usually 
need a higher number of medicines, seem to be using more than one source of supply 
to obtain all the medicines they need. 
Lower total availability of medicines in the three models of pharmacies in the Northeast 
shows the persistence of regional inequalities. Better total availability for men in FSUS may 
be related to lower number of medicines used by men compared to women, as observed in 
studies on use of medicine in Brasil3,25.
Although general acceptability to the three models of provision has been high (> 90.0%), 
regional differences found between the FSUS and the FPFP indicate the need to direct efforts 
to improve the quality of service in these provision sources, especially in the North and 
Northeast. As the number of pharmacies participating in the Popular Pharmacy Program is 
much higher than that of the public network, it is necessary to establish measures to ensure 
the quality of service to their users9,24. 
c Set of medicines available at 
the Farmácia Popular Public 
network: http://portalsaude.
saude.gov.br/images/pdf/ 
2014/fevereiro/20/ 
elenco-fp1-20-08-12.pdf
d Set of free medicines in the 
Farmácia Popular private associated 
pharmacies: http://portalsaude.
saude.gov.br/images/pdf/2014/
dezembro/11/rol-medicamentos-
SNTP-11122014.pdf
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The price of medicines, which is determined both by market-related factors and by 
the affordability of families and governments, represents a barrier to access, because it 
affects the capacity of individuals, families, and public and private providers to pay for 
them. In this study, although the financial barrier explains much of the partial and null 
access, its magnitude was low. This result indicates that the national policy of medicines 
and of pharmaceutical services implemented in the country since 1999 seems to be 
achieving its objective of ensuring access to free or affordable medicines for most of the 
population with NCD. Previous studies reported higher percentages of non-purchasing 
of prescription medicines due to financial difficulty, suggesting that the situation may 
have improved in recent years1,6,8,19.
Regarding the limitations of this study, in addition to those specific to household surveys, 
discussed in the methodological article of the PNAUM18, one of the limitations was the use of 
self-reported measures and restricted to the cases of individuals with NCD who already had 
medical diagnosis and indication of treatment. Thus, lack of access to diagnosis and prescription 
may have been a barrier to access to medicines, which was not captured in this study. 
Another limitation was the fact that only those who used the pharmacy services to obtain 
the medicines reported at the time of the interview were considered in the assessment 
of availability, accessibility, and acceptability in each of them. The methodological choice 
of not using recall period may have generated a selection bias due to no inclusion of 
individuals who, perchance, had used the services of pharmacies prior to the interview 
and that could have a perception or assessment that was different from that observed. 
Acceptability was investigated considering the characteristics of pharmacy services, but 
not of the products. 
In conclusion, full access to medicines to treat the NCD analyzed in this study was very 
high. Geographic accessibility to pharmacies was reasonable and can improve, especially 
for the FSUS and FPFP in the North, Northeast, and Midwest. Difference was observed for 
total availability between the three services investigated, indicating the need to promote 
improvement in the supply system of SUS pharmacies, especially in the North and Northeast. 
Users’ acceptability was very good or good for the three services; however, regional differences 
suggest the need to promote better quality for FSUS in the North, Northeast, and Midwest 
and for FPFP in the North. Affordability was very good. The theoretical model, applied for 
the first time in a household survey and exclusively using self-reported information, enabled 
observing the complexity involved in the dynamics of obtaining access, as well as identifying 
barriers to access in the dimensions analyzed.
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